Floatz logo

Methylphenidate

Methylphenidate

University Hospital, ToursSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Methylphenidate cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Methylphenidate is also rated in:

attention deficit-hyperactivity disorderDormant
BBB
Indicative ·
76 / 100
View asset →
ApathyDormant
BBB
Indicative ·
72 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →